Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
September 14, 2024 03:00 ET
|
Immunocore Holdings plc
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with...
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
September 14, 2024 03:00 ET
|
Sutro Biopharma, Inc.
- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian...
Hologram Doctor-Patient Visits Launched by West Cancer Center
September 13, 2024 09:20 ET
|
Proto
Berkeley, CA, Sept. 13, 2024 (GLOBE NEWSWIRE) -- West Cancer Center & Research Institute and Proto Inc. announced the first holographic doctor-patient visits at UC Berkeley’s forum on Global...
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
September 12, 2024 16:05 ET
|
Immuneering Corporation
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line
Biosplice Therapeutics Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
September 12, 2024 07:00 ET
|
Biosplice Therapeutics, Inc.
Biosplice Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
IGI Announces Publication in Nature Cancer on ISB 2001, IGI's Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma
September 11, 2024 05:00 ET
|
Ichnos Glenmark Innovation
Preclinical data in Nature Cancer showed IGI's ISB 2001 can potentially overcome myeloma cell escape mechanisms to evade therapeutic anti-tumor activity
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
September 09, 2024 17:00 ET
|
Regeneron Pharmaceuticals, Inc.
Late-breaking data at WCLC show Libtayo monotherapy nearly doubled median overall survival and reduced the risks of death and disease progression by 41% and 50%, respectively, compared to chemotherapy...
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
September 09, 2024 11:45 ET
|
Boehringer Ingelheim
Beamion LUNG-1, Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded independent central review (BICR)1Preliminary activity in...
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
September 09, 2024 07:00 ET
|
Regeneron Pharmaceuticals, Inc.
At WCLC, five-year survival data to be presented on Libtayo (PD-1 inhibitor) first-line monotherapy in advanced non-small cell lung cancer At ESMO, longer-term results with investigational fianlimab...
Antibody Drug Conjugates Market Is Expected To Reach Revenue Of USD 51.2 Bn By 2033, at 15.8% CAGR: Dimension Market Research
September 05, 2024 11:45 ET
|
Dimension Market Research
New York, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Overview The Global Antibody Drug Conjugates (ADCs) Market is projected to grow from USD 13.7 billion in 2024 to USD 51.2 billion by 2033, at a CAGR...